Neogen (NEOG): 40% Undervalued Despite FDA Warning

NEOG stock analysis: 60% earnings beat signals turnaround — full deep dive

👉 Want this level of research on ANY COMPANY IN THE WORLD... for FREE? Check us out at: https://flash.stocksentinel.ai/?utm_source=rss_video&utm_medium=explainer_video&utm_campaign=freja_and_friends

In this deep dive, we break down Neogen Corporation (NEOG) and its operational turnaround driven by a Q1 revenue beat and the $160 million divestiture of its genomics division. With core organic revenue growing 8.1% YoY and Adjusted EBITDA margins expanding to 18.7%, the key question for investors is whether manufacturing internalization can overcome recent FDA regulatory scrutiny. Here’s everything you need to know before making a decision on NEOG.

🎯 SECTIONS:

- Executive Summary & Company Overview

- Food Safety & Animal Safety Revenue Drivers

- Q1 FY2027 Financial Results & Guidance Revisions

- Manufacturing Internalization & Lansing Transition

- Valuation Metrics & Debt De-leveraging Outlook

- FDA Warning Letter & Regulatory Risk Analysis

- 5-Year Bull, Base & Bear Scenario Modeling

- Final Investment Thesis & Price Target